Fundamental Analysis of Verona Pharma PLC - Growth / Value Index
VRNA - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 18.75
Price to Book Ratio of 27.04 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -102.84 | -162639.18 | -1453117353.30 % | |
| Price to Book | 25.33 | 33070.26 | 991090 % | 37.31 |
| Price to Sales | 6937.94 | 17999682 | 1072118464 % | |
| Enterprise Value to EBITDA Multiple | -13.22 | -170308.91 | -2095006019.68 % |
VRNA - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -24.63 | -20.33 | 99.93 % | -11.46 |
| Return On Asset | -20.90 | -16.45 | 99.94 % | -8.90 |
| Net Profit Margin | -6746.41 | -11067.25 | 26.22 % | 0 |
| Operating Profit Margin | -7372.33 | -13680.79 | 17.28 % | 0 |
| EBITDA Margin | -6693.22 | -10568.56 | 28.66 % | 0 |
Highlights
| Market Cap | 1054.06 M |
| Enterprise Value | 831845 K |
| Price/Book TTM | 25.33 |
| Outstanding Share | 81081.80 K |
| Float/ Outstanding Share | 632.81% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 2.00 |
| Altman Z Score | 9.55 |
| Sloan Ratio | -0.0102 |
| Peter Lynch Fair Value | 0 |
VRNA - Growth Highlights
Growth Analysis
Steady increase in Total Assets for last 3 Years
Quarterly sales in last 5 Quarter is trending down
Companies' sales dropped by 99.90 % from last year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 940056 | 99.90 % | 100.00 % |
| Gross Profit | -784262.00 | 100.61 % | 25.28 % |
| EBITDA | -62920.00 K | 99.93 % | 99.59 % |
| Net Profit | -63420.00 K | 99.93 % | 82.52 % |
| EPS | -0.126 | 100.00 % | NA |
VRNA - Stability Highlights
Stability Analysis
Altman Z Score of 9.77 suggests good Stability
Cash ratio of 31.27
Company financial liquidity has improved
Company is unable to generate enough free cash to support the business.
Interest Coverage of -29.46
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.199 | 338.70 % | 0.221 |
| Cash Ratio | 31.27 | 161.15 % | |
| Quick Ratio | 33.33 | 163.72 % | 18.40 |
| Shareholders Equity | 80.90 | -8.92 % | |
| Debt to EBITDA | -1.02 | -665024.33 % |
Historical Valuation Ratios of Verona Pharma PLC
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Verona Pharma PLC
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Verona Pharma PLC
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Verona Pharma PLC
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)